Stocks · News reference
Visara secures exclusive worldwide rights, excluding Greater China, from Wuhan Hiteck Biological Pharma to develop and commercialize HT006.2.2Visara plans to develop HT006.2.2 as VIS-102, its second clinical-stage
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Hiteck grants Visara, a majority-owned ophthalmology subsidiary of NovaBridge Biosciences (NASDAQ:NBP), exclusive worldwide rights, excluding Greater China, to develop and commercialize HT006.2.2Hiteck retains all
NovaBridge Biosciences (NASDAQ:NBP) held its quarterly earnings conference call on Thursday. Below is the complete transcript from the call. This content is powered by Benzinga APIs. For comprehensive financial data and